Agilent Technologies (FRA:AG8) Research & Development: €405 Mil (TTM As of Apr. 2026)


FRA:AG8 Agilent Technologies Inc FRA:AG8
91 GF Score
Price €119.35
GF Value €127.48
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Agilent Technologies Research & Development?

Agilent Technologies FRA:AG8 -0.25% 91 Research & Development is €405 Mil as of Apr. 2026. GuruFocus rates FRA:AG8 with a GF Score™ of 91/100 and a GF Value™ of €127.48 (Fairly Valued). The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Agilent Technologies's Research & Development for the three months ended in Apr. 2026 was €108 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Apr. 2026 was €405 Mil.

Agilent Technologies  (FRA:AG8) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Agilent Technologies Research & Development Related Terms

Agilent Technologies Research & Development Historical Data

* Premium members only.

The historical data trend for Agilent Technologies's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Agilent Technologies Research & Development Chart

Agilent Technologies Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 380.14 474.01 455.51 439.72 390.85

Agilent Technologies Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 99.68 95.13 102.22 99.57 107.73
FRA:AG8
91GF Score
Agilent Technologies Inc FRA:AG8
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Agilent Technologies Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €405 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €405 Mil mean?
Agilent Technologies (FRA:AG8) has a Research & Development of €405 Mil as of Apr. 2026. Research and development expense is the total cost for research and development activities. View historical data on Agilent Technologies and its competitors.
Is Agilent Technologies' Research & Development too high?
Agilent Technologies' current Research & Development is €405 Mil. Overall, Agilent Technologies has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Agilent Technologies' Research & Development compare to WAT and IDXX?
Agilent Technologies' Research & Development of €405 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Diagnostics & Research company?
A good Research & Development depends on the Medical Diagnostics & Research industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Agilent Technologies and its competitors. Agilent Technologies's current Research & Development is €405 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agilent Technologies stock overvalued right now?
Based on GuruFocus' analysis, Agilent Technologies (FRA:AG8) is currently considered Fairly Valued. The stock's GF Value™ is €127.48, compared to a current price of €119.35 — trading 6.4% below its estimated fair value. The current Research & Development is €405 Mil. Agilent Technologies' overall GF Score™ is 91/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Agilent Technologies (FRA:AG8), the current Research & Development is €405 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Agilent Technologies (FRA:AG8) Overvalued in 2026?

Based on GuruFocus' analysis, Agilent Technologies stock appears to be undervalued. The current stock price of €119.35 is trading 6.4% below its estimated GF Value™ of €127.48. GuruFocus considers Agilent Technologies to be Fairly Valued.

Key valuation signals for FRA:AG8:

  • Research & Development: €405 Mil
  • GF Value™: €127.48 vs. price of €119.35 (6.4% below fair value)
  • GF Score™: 91/100 with 1 warning sign

No single metric tells the full story. See the FRA:AG8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Agilent Technologies Business Description

Address 5301 Stevens Creek Boulevard, Santa Clara, CA, USA, 95051
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and diagnostics, cross lab operations consisting of consumables and services, and applied end markets. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
91GF Score

Get the complete analysis for FRA:AG8

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€119.35
Price
€127.48
GF Value